News | February 23, 2022
Biorchestra announces US$45 million series C fundraising
he financing was significantly oversubscribed with high demand from both existing and new investors.
he financing was significantly oversubscribed with high demand from both existing and new investors.
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
The sale is expected to close in the first quarter of 2022
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The facility will manufacture its Herceptin biosimilar, Tuznue
New inhalers would have near-zero Global Warming Potential propellant
US $ 555,000 invested by Wavemaker Partners in pre-seed round
Subscribe To Our Newsletter & Stay Updated
